Number of pages: 100 | Report Format: PDF | Published date: May 15, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
Report Attribute |
Details |
Market Size Value in 2022 |
US$ 1.90 billion |
Revenue Forecast in 2031 |
US$ 2.97 billion |
CAGR |
5.1% |
Base Year for Estimation |
2022 |
Forecast Period |
2023 to 2031 |
Historical Year |
2021 |
Segments Covered |
Type, End User and Region |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global Nipah virus (NiV) infection testing market was valued at US$ 1.90 billion in 2022 and is expected to register a revenue CAGR of 5.1% to reach US$ 2.97 billion by 2031.
Nipah Virus (NiV) Infection Testing Market Fundamentals
Nipah virus infection testing refers to the diagnostic procedures used to detect and confirm the presence of the Nipah virus in individuals suspected of being infected. The Nipah virus is a zoonotic virus that can cause severe respiratory illness and human encephalitis. The testing methods aim to identify the virus's genetic material or specific antibodies the immune system produces in response to the infection. Nipah virus infection testing is typically performed in specialized laboratories equipped with appropriate biosafety precautions due to the high level of contagion and potential for severe disease associated with the virus.
The global Nipah virus (NiV) infection testing industry analysis report comprehensively analyzes the market, with the factors that either aid or impede the market growth, such as its drivers, restraints, and opportunities. The research provides insight into the companies that operate in the Nipah virus (NiV) infection testing market and their efforts to position themselves as key players through expansion strategies and innovations. It also highlights recent developments that contribute to the Nipah virus (NiV) infection testing market growth. The research also analyzes the impact of the COVID-19 pandemic.
This research is valuable for businesses seeking insights into the market, customers, and competition. The research provides special insights into the segmentation, regions, market size & projection, revenue CAGRs, and other important information that may help clients make the right decisions. The report assembles data from market players and professionals across the industrial value chain. The study also incorporates qualitative and quantitative assessments from industry professionals. Secondary research, surveys and interviews, and statistical modeling are all used in our research to estimate market size and projection. Our reports deliver the most reliable market data because of our specialized research methods.
[1222]
Nipah Virus (NiV) Infection Testing Market Dynamics
Nipah virus outbreaks have occurred sporadically in different regions, causing significant public health concerns. The potential for severe illness, high mortality rates, and possible person-to-person transmission during outbreaks create a strong demand for rapid and accurate diagnostic tests. Timely detection and identification of Nipah virus cases are crucial for effective outbreak control. According to the WHO, the fatality rate of the Nipah virus is estimated at 40% to 75%. Depending on local epidemiological surveillance and clinical management capabilities, this rate can vary by the outbreak. The global healthcare community recognizes the importance of preparing for emerging infectious diseases. The Nipah virus has gained significant attention due to its potential for large-scale outbreaks and the lack of specific antiviral treatments or vaccines. This awareness has led to increased investments in research and development of diagnostic technologies, including testing methods for Nipah virus infection. Moreover, advancements in diagnostic technologies, such as molecular biology techniques and point-of-care testing, have contributed to the market growth for Nipah virus infection testing. These technologies allow for faster and more accurate detection of viruses, enabling healthcare providers to promptly initiate appropriate patient management strategies. Governments and public health agencies play a crucial role in driving the market for Nipah virus infection testing. They invest in research, development, and procurement of diagnostic tools to strengthen their healthcare systems' preparedness and response capabilities. Additionally, funding agencies and organizations often support research projects and collaborations to develop innovative testing methods for emerging infectious diseases like the Nipah virus.
However, the cost of Nipah virus diagnostic tests can be a significant restraint, particularly in resource-limited settings. Advanced molecular and serological testing methods may require specialized equipment, reagents, and trained personnel, contributing to higher costs. Nipah virus outbreaks have been mostly localized to specific regions, primarily in Southeast Asia and South Asia. This geographic constraint has impacted the global demand for Nipah virus diagnostic tests, hindering the global Nipah virus (NiV) infection testing market growth.
Nipah Virus (NiV) Infection Testing Market Ecosystem
Nipah Virus (NiV) Infection Testing Market, by Test Type
Nipah Virus (NiV) Infection Testing Market, by End User
Nipah Virus (NiV) Infection Testing Market by Test Type
[1212]
ELISA is a well-established and widely used technology in diagnostic testing. It has been extensively validated and standardized for various infectious diseases, including viral infections. ELISA kits for Nipah virus testing leverage this established technology, making them readily available and trusted by healthcare professionals. ELISA kits have demonstrated high sensitivity and specificity in detecting specific antibodies against the Nipah virus. They can detect the presence of Nipah virus-specific IgM and IgG antibodies in patient samples, indicating current or past infections. The reliable performance of ELISA kits in terms of accuracy and precision contributes to their dominance in the market. According to the National Center For Biotechnology Information, anti-Nipah IgM and IgG ELISAs have demonstrated high accuracy in Nipah virus infection testing. These ELISA assays showed a specificity of 99.28% and a sensitivity of 100% when compared to the reference test from the Centers for Disease Control and Prevention (CDC) in the U.S. Additionally, the assays exhibited a negative predictive value of 100% and positive predictive values of 90% for anti-Nipah IgM ELISA and 93.94% for anti-Nipah IgG ELISA. Overall, the test accuracy of these ELISA assays was calculated to be 99.33%. Moreover, ELISA testing for the Nipah virus has been incorporated into established testing protocols and guidelines. Public health agencies and organizations, such as the WHO, recommend using ELISA for serological diagnosis of Nipah virus infection. These standardized testing protocols promote the widespread adoption of ELISA kits as the preferred testing method.
Segmentation of the market refers to the division of the industry into subgroups based on factors such as test type, end user. Market segmentation data helps businesses to understand the preferences and unique needs of different customer groups and develop targeted sales strategies. This information also helps in identifying potential Nipah virus (NiV) infection testing market growth opportunities.
Nipah Virus (NiV) Infection Testing Market by Region
The Asia Pacific region is expected to register a lucrative revenue share of the Nipah virus (NiV) infection testing market, it accounted for ~42% of the market share. The Asia Pacific region has experienced several Nipah virus outbreaks, particularly in Bangladesh, India, Malaysia, and Singapore. The high incidence of these outbreaks creates a strong demand for Nipah virus infection testing in the region. Timely and accurate diagnosis is crucial for effective outbreak control, leading to increased market demand for testing kits and diagnostic services. According to the National Center For Biotechnology Information, 639 human Nipah virus (NiV) infection cases have been reported in various countries. Among these, Bangladesh accounted for 261 cases, India for 85 cases, Singapore for 11 cases, the Philippines for 17 cases, and Malaysia for 265 cases. The overall mortality rate associated with these cases is approximately 59%. Governments in the Asia Pacific region are actively involved in funding initiatives related to infectious disease control, including the Nipah virus. Moreover, collaborative research efforts among academic institutions, government bodies, and industry players are driving advancements in Nipah virus testing in the Asia Pacific region.
Based on the regions, the global Nipah virus (NiV) infection testing market is segmented into:
The industry's regional segmentation provides insights into geographic pockets in terms of Nipah virus (NiV) infection testing industry trends, market size, share, and growth rate. This information helps organizations assess potential growth opportunities in new regional markets, understand competitive threats, and develop localized sales and expansion strategies. This section also offers deeper insights into the regional and country-level Nipah virus (NiV) infection testing market overview.
Key Components of the Report
Nipah Virus (NiV) Infection Testing Market Competitive Landscape
The market competitive landscape analysis is performed by gathering and evaluating data about the key competitors, industry trends, and market dynamics. It involves collecting and analyzing data on factors such as products, pricing, geographic reach, customer demographics, marketing tactics, and recent developments. Competitive landscape analysis can help organizations identify present or prospective opportunities and risks in the market.
Nipah Virus (NiV) Infection Testing Market Strategic Developments
Reasons To Buy This Report
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Nipah virus infection testing refers to the diagnostic procedures used to detect and confirm the presence of the Nipah virus in individuals suspected of being infected.
Asia Pacific can be considered the key growth region due to the surge in Nipah virus (NiV) infection testing industry trends in China, Japan, and the Indian subcontinent.
The Nipah virus (NiV) infection testing market is expected to register a revenue CAGR of 5.1% during the forecast period from 2023 to 2031.
There is a continuous need to develop advanced and innovative diagnostic technologies for Nipah virus infection testing. This includes exploring new testing methods such as molecular assays, point-of-care, and rapid diagnostic tests.
Strategic collaborations and partnerships are formed between market players, research institutions, and government organizations to leverage combined expertise and resources. These collaborations facilitate knowledge sharing, access to new markets, and the development of comprehensive testing solutions.
The Nipah virus (NiV) infection testing market was valued at US$ 1.90 billion in 2022
The estimated size of the global Nipah virus (NiV) infection testing market in 2031 is US$ 2.97 billion.
The prominent players operating in the global Nipah virus (NiV) infection testing market are F.Hoffmann-La Roche Ltd, Liferiver Bio-Tech (United States) Corp., Molbio Diagnostics Pvt. Ltd., MyBioSource and Krishgen Biosystems.
The ELISA Kits segment dominated the Nipah virus (NiV) infection testing market.
*Insights on financial performance are subject to the availability of information in the public domain